We are live on ! Find out more
NCM

Nantahala Capital Management Portfolio holdings

AUM $2.72B
1-Year Est. Return 121.58%
This Fund
S&P 500
This Quarter Est. Return
+19.43%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.75B
AUM Growth
+$77.9M
Cap. Flow
-$78.7M
Cap. Flow %
-4.49%
Top 10 Hldgs %
55.92%
Holding
150
New
22
Increased
25
Reduced
39
Closed
26

Top Buys

Rank Stock Value
1
PTON icon
Peloton Interactive
PTON
+$15.1M
2
TRML
Tourmaline Bio
TRML
+$10.2M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$6.91M
4
EHTH icon
eHealth
EHTH
+$6.1M
5
CONN
Conn's Inc.
CONN
+$6.03M

Top Sells

Rank Stock Value
1
ESTA icon
Establishment Labs
ESTA
+$20.3M
2
SLNO
Soleno Therapeutics
SLNO
+$20.2M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$19.5M
4
LXFR icon
Luxfer Holdings
LXFR
+$10.1M
5
CYTK icon
Cytokinetics
CYTK
+$9.19M

Sector Composition

Rank Sector Weight
1 Healthcare 36.87%
2 Consumer Discretionary 8.07%
3 Financials 4.11%
4 Communication Services 3.43%
5 Technology 2.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NNBR icon
51
NN Inc
NNBR
$313M
$6.67M 0.38%
1,406,446
-776
-0.1% -$3.56K
EGRX
52
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$6.6M 0.38%
+1,258,762
New +$6.91M
RDI icon
53
Reading International Class A
RDI
$34.3M
$6.23M 0.36%
3,385,253
-16,950
-0.5% -$32.2K
TELA icon
54
TELA Bio
TELA
$37M
$6.22M 0.36%
1,097,866
– –
ZYXI
55
DELISTED
Zynex
ZYXI
$6.06M 0.35%
490,000
+370,000
+308% +$4.44M
CONN
56
DELISTED
Conn's Inc.
CONN
$5.93M 0.34%
1,769,997
+1,410,626
+393% +$6.03M
TARS icon
57
Tarsus Pharmaceuticals
TARS
$3B
$5.46M 0.31%
150,321
-224,955
-60% -$6.61M
COGT icon
58
Cogent Biosciences
COGT
$6.74B
$5.32M 0.3%
790,936
+150,000
+23% +$927K
ALTG icon
59
Alta Equipment Group
ALTG
$245M
$5.21M 0.3%
402,509
+100,000
+33% +$1.15M
ELUT icon
60
Elutia
ELUT
$35.7M
$5.2M 0.3%
1,650,000
– –
AGS
61
DELISTED
PlayAGS
AGS
$5.09M 0.29%
566,588
– –
HLF icon
62
CALL
Herbalife
HLF
$1.21B
$5.03M 0.29%
500,000
-100,000
-17% -$1.08M
DHX icon
63
DHI Group
DHX
$160M
$5.01M 0.29%
1,966,417
-673,270
-26% -$1.68M
NSPR icon
64
InspireMD
NSPR
$38.4M
$4.9M 0.28%
2,066,456
– –
XTNT icon
65
Xtant Medical Holdings
XTNT
$46.3M
$4.68M 0.27%
4,000,000
– –
ENVA icon
66
Enova International
ENVA
$6.39B
$4.52M 0.26%
71,865
– –
THTX
67
DELISTED
Theratechnologies
THTX
$4.45M 0.25%
2,682,228
– –
SLN
68
Silence Therapeutics
SLN
$717M
$4.32M 0.25%
+200,000
New +$4.35M
MLYS icon
69
Mineralys Therapeutics
MLYS
$2.4B
$4.29M 0.25%
+332,506
New +$4.11M
VNDA icon
70
Vanda Pharmaceuticals
VNDA
$298M
$4.16M 0.24%
1,013,251
– –
NAMS icon
71
NewAmsterdam Pharma
NAMS
$3.42B
$4.14M 0.24%
+175,000
New +$3.55M
DRIO icon
72
DarioHealth
DRIO
$74.4M
$4.03M 0.23%
131,628
+14,790
+13% +$561K
XBI icon
73
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$3.99M 0.23%
+42,069
New +$3.9M
ABEO icon
74
CALL
Abeona Therapeutics
ABEO
$427M
$3.77M 0.22%
520,000
– –
NGNE icon
75
Neurogene
NGNE
$667M
$3.68M 0.21%
72,279
– –
1 2
3
4 5

Similar funds

TAM
Timucuan Asset Management Jacksonville, Florida $2.72B AUM 4.95% 1-Year Est. Return
XL
XN LP New York $2.72B AUM 46.67% 1-Year Est. Return
NB
Nicolet Bankshares Green Bay, Wisconsin $2.71B AUM 17.55% 1-Year Est. Return
PA
Profund Advisors Bethesda, Maryland $2.72B AUM 47.27% 1-Year Est. Return
BCM
Bowie Capital Management Richardson, Texas $2.71B AUM 5.42% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
GC
Giverny Capital Montreal, Quebec, Canada $2.73B AUM 14.09% 1-Year Est. Return

Nantahala Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Nantahala Capital Management held 150 positions worth $1.75B, up 4.7% from $1.67B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Nantahala Capital Management withdrew a net $78.7M in Q1 2024, closing 26 positions and reducing 39 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $19.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Nantahala Capital Management opened a new position in Eagle Pharmaceuticals, Inc. worth $6.6M.

  • Nantahala Capital Management's largest Q1 2024 buy was Eagle Pharmaceuticals, Inc.: 1,258,762 shares worth $6.6M.
  • Nantahala Capital Management added most to Peloton Interactive in Q1 2024, an estimated $15.1M increase.
  • Nantahala Capital Management's biggest Q1 2024 reduction was Establishment Labs, cutting an estimated $20.3M.
  • Nantahala Capital Management fully exited iShares Russell 2000 ETF in Q1 2024, selling an estimated $19.5M.
  • Nantahala Capital Management's ten largest holdings make up 56% of its $1.75B portfolio in Q1 2024.
  • Nantahala Capital Management opened 22 new positions and closed 26 in Q1 2024.
  • Nantahala Capital Management's portfolio value rose 4.7% quarter-over-quarter to $1.75B.

Based on Nantahala Capital Management's 13F filing for Q1 2024, filed 15 May 2024.